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This study detected reduced nerve growth factor (NGF)
expression within gastric endothelial cells in both elderly
patients and aged rats. Reduced NGF correlated with impaired
angiogenesis and delayed gastric ulcer healing in aged rats.
The defects could be reversed by exogenous NGF via
phosphoinositide-3 kinase/serine threonine kinase signaling
protein, and mammalian target of rapamycin signaling, and
was dependent on serum response factor. These data show
that down-regulation of endothelial NGF expression in aging is
a significant contributor to impaired gastric mucosal repair.
BACKGROUND & AIMS: Aging gastric mucosa has increased
susceptibility to injury and delayed healing owing to impaired
angiogenesis, but the mechanisms are not fully known. We
examined whether impairment of angiogenesis in aging gastric
mucosa is caused by deficiency of nerve growth factor (NGF) in
gastric endothelial cells (ECs), and whether NGF therapy could
reverse this impairment.
METHODS: In gastric mucosal ECs (GECs) isolated from
young and aging rats we examined the following: (1) in vitro
angiogenesis, (2) NGF expression, and (3) the effect of NGF
treatment on angiogenesis, GEC proliferation and migration,and dependence on serum response factor. In in vivo studies in
young and aging rats, we examined NGF expression in gastric
mucosa and the effect of NGF treatment on angiogenesis and
gastric ulcer healing. To determine human relevance, we
examined NGF expression in gastric mucosal biopsy specimens
of aging (70 y) and young (40 y) individuals.
RESULTS: In cultured aging GECs, NGF expression and angio-
genesis were reduced significantly by 3.0-fold and 4.1-fold vs
young GECs. NGF therapy reversed impairment of angiogenesis
in aging GECs, and serum response factor silencing completely
abolished this response. In gastric mucosa of aging rats, NGF
expression in GECs was reduced significantly vs young rats. In
aging rats, local NGF treatment significantly increased angio-
genesis and accelerated gastric ulcer healing. In aging human
subjects, NGF expression in ECs of gastric mucosal vessels was
5.5-fold reduced vs young individuals.
CONCLUSIONS: NGF deficiency in ECs is a key mechanism
underlying impaired angiogenesis and delayed ulcer healing in
aging gastric mucosa. Local NGF therapy can reverse these
impairments. (Cell Mol Gastroenterol Hepatol 2018;6:199–213;
https://doi.org/10.1016/j.jcmgh.2018.05.003)
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https://doi.org/10.1016/j.jcmgh.2018.05.003Omucosa of aging individuals, which we termed
aging gastric mucosa or aging gastropathy,1,2 has increased
susceptibility to injury and delayed healing owing to
impaired angiogenesis,1,3–6 but the mechanisms are not fully
elucidated. Angiogenesis (new blood vessel formation) is a
fundamental process that is essential for reproduction,
postnatal growth, and tissue injury healing.7–13 Angiogen-
esis is impaired in aging tissues including aging gastric
mucosa and results in inadequate revascularization and
delayed injury healing.3,14,15 Vascular endothelial growth
factor (VEGF) A is a fundamental regulator of angiogenesis
in general,16–19 and in injured and ulcerated gastric
mucosa.3,12,13 Our previous studies have shown that
angiogenesis in vivo and in vitro is reduced dramatically in
the gastric mucosa of aging rats, and showed that reduced
VEGF expression in endothelial cells (ECs) is one of the
mechanisms.3,4 Nevertheless, treatment with VEGF only
partly reversed impaired angiogenesis in aging gastric ECs,4
indicating an essential role for other factor(s) in addition
to VEGF. Neither the identity of such a factor nor its
mechanism of action has been fully explored.
Nerve growth factor (NGF), originally discovered by the
1986 Nobel Laureate Rita Levi-Montalcini20,21 as a factor
critical for growth and survival of neurons, has gained atten-
tion in recent years for its actions that extend beyond the
promotion of neuronal survival and outgrowth.22,23 One such
non-canonical action of NGF is the ability to promote angio-
genesis in brain capillary ECs.24 The expression of NGF in
aging gastric ECs and themechanistic role of NGFdeficiency in
impaired angiogenesis of aging gastric ECs are not known.
Because gastric mucosal ECs (GECs) are the key cellular
targets and effectors of gastric angiogenesis, this study
aimed to determine whether reduced NGF expression in
aging GECs is a primary cause of the impaired angiogenesis
in aging gastric mucosa, and whether NGF therapy can
reverse aging-related impairment of angiogenesis in vitro.
We examined the expression of NGF in ECs isolated from
gastric mucosa of young and aging rats, and the cellular and
molecular mechanisms of NGF action on aging GECs,
including the effect of NGF treatment on GEC migration,
G-actin to F-actin polymerization, stress fiber formation,
proliferation, and angiogenesis. We also examined whether
signaling pathways phosphoinositide-3 (PI3) kinase/serine
threonine kinase signaling protein (Akt) and mammalian
target of rapamycin (mTOR) are involved and the require-
ment of serum response factor (SRF) for these NGF actions.
In in vivo studies, we examined the expression of NGF in
gastric mucosa of young and aging rats, and the effect of
local treatment with NGF on in vivo angiogenesis, gastric
ulcer healing, and mucosal regeneration in aging rats.
Here, we show that aging GECs have significantly reduced
expression of NGF and reduced angiogenesis compared with
youngGECs, and thatNGFdeficiency is a key cause of impaired
angiogenesis because NGF gene therapy completely reversed
this impairment. Furthermore, our study showed that NGF’sangiogenic action involves PI3 kinase/Akt and mTOR, en-
compasses G actin to F actin polymerization and stress fiber
formation, and is critically dependent on SRF. Our in vivo
studies in rats showed reducedNGFexpression inECs of blood
vessels in both uninjured and ulcerated gastric mucosa of
aging rats compared with young rats. In aging rats, local
treatment of NGF at the base of gastric ulcers significantly
increased mucosal blood flow and angiogenesis, accelerated
ulcer healing, and improved mucosal regeneration. We also
demonstrated the human relevance of our experimental
findings by showing reduced NGF expression in gastric ECs in
gastric mucosal biopsy specimens of aging (age, 70 y) vs
young (age, 40 y) individuals.
Materials and Methods
Study Approval
All experimental studies in rats were approved by the
institutional animal review committees: subcommittees for
Animal Studies of the VA Long Beach Healthcare System
(Long Beach, CA) and the Jagiellonian University Medical
College (Krakow, Poland). Rats received humane care based
on the National Institutes of Health recommendations out-
lined in the Guide for the Care and Use of Laboratory Ani-
mals. The use of archival human gastric mucosal biopsy
specimens for immunostaining was approved by the Insti-
tutional Review Board of the Veterans Affairs Medical Cen-
ter (Long Beach, CA). The human gastric biopsy specimens
did not have any specific patient identifiers and the only
inclusion criteria used were age, normal appearance on
histology, and the lack of Helicobacter pylori and inflam-
mation in mucosal biopsy specimens.
All authors had access to the study data and reviewed
and approved the final manuscript.
Isolation of Gastric Mucosal ECs
GECs were isolated from Fisher F-344 rats (purchased
from the National Institute on Aging, Bethesda, MD), 3
months of age (referred to as young GECs) and 24 months of
age (referred to as aging GECs) using Platelet Endothelial
Cell Adhesion Molecule-1 (PECAM-1/CD31) selection and
magnetic bead separation as described previously.4 ECs
were identified by positive staining for Factor VIII–related
antigen, CD31, and VEGF-R2, and by absence of staining
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were grown on collagen-coated dishes in EC growth media
containing fetal bovine serum, heparin, and endothelial cell
growth supplements. For some studies, GECs were treated
with the specific PI3 kinase inhibitor 50 mmol/L for 30 mi-
nutes; Cell Signaling Technology, Danvers, MA), the mTOR
inhibitor rapamycin (10 nmol/L for 60 minutes; Cell
Signaling Technology), Latrunculin B (0.5 mmol/L for 30
minutes; Invitrogen, Carlsbad, CA; inhibitor of actin poly-
merization), or recombinant rat NGF (10–1000 ng/mL; R&D
Systems, Minneapolis, MN). Cell viability was examined us-
ing Calcein AM live cell tracking dye (10 mmol/L; Invitrogen)
as described in our previous study.25 At the end of each
treatment, GECs were incubated with Calcein AM (10 mmol/
L) for 15 minutes at 37C. After fixation in 4% para-
formaldehyde for 20 minutes, the cells were washed,
mounted on glass coverslips with Prolong Gold (Molecular
Probes, Thermo Fisher Scientific, Waltham, MA), and were
examined using the AxioImager2 fluorescence microscope
imaging system (Carl Zeiss, Thornwood, NY). Fluorescence
staining intensity was quantified using the MetaMorph 7.0
imaging system (Molecular Devices, Downington, PA). The
total cell count and the number of Calcein AM stained cells
were determined in 5 randomly selected fields. Cell viability
was expressed as the percentage of Calcein AM–stained cells.
In Vitro Angiogenesis Assay
Endothelial tube formation on growth factor–reduced
Matrigel was determined using an in vitro angiogenesis
assay similar to our previous studies.4,26 ECs were grown in
complete growth medium in 60-mm tissue culture dishes
until they were approximately 80% confluent. The growth
medium was replaced with basal medium supplemented
with 1% fetal bovine serum and antibiotics, and the cells
were cultured for 18 additional hours. The cells then were
trypsinized, counted, resuspended in basal medium sup-
plemented with 1% fetal bovine serum, and seeded onto
growth factor–reduced Matrigel in 48-well culture plates for
up to 24 hours. Six and 24 hours later, the seeded cells were
photographed using a Nikon inverted phase-contrast pho-
tomicroscope (Nikon USA, Garden City, NY) and analyzed
using a video image analysis system (MetaMorph 7.0). Tube
formation was quantified by measuring the total pixel length
of the capillary tubes in 5 randomly selected standardized
fields for each well under 200 magnification.
EC Proliferation
Cell proliferation was determined by bromodeoxyur-
idine (BrdU) assay using a commercially available kit (EMD
Millipore Corporation, Billerica, MA) according to the man-
ufacturer’s instructions. The total cell count and the number
of BrdU-positive cells were determined in 5 randomly
selected fields. Cell proliferation was expressed as the per-
centage of BrdU-positive cells.
Reverse-Transcription Real-Time Quantitative
Polymerase Chain Reaction
Total cellular RNA was isolated from young and aging
GECs using TRIzol reagent (Invitrogen). Total RNA (1 mg) wastreated with deoxyribonuclease I and reverse-transcribed
using the GeneAmp RNA-PCR kit (Applied Biosystems, Fos-
ter City, CA) as described in our previous studies.1,4 The
mRNA levels of NGF and b-actin were quantified by real-time
polymerase chain reaction (PCR) using prevalidated Quanti-
Tect assays (Qiagen, Valencia, CA) and the iCycler real-time
PCR detection system (Bio-Rad, Hercules, CA). For negative
controls, we used no template control and no reverse-
transcriptase controls, which did not show any detectable
mRNA expression in the reverse-transcription PCR assays.
Relative mRNA levels were calculated using the 2-DCt method
and normalized to b-actin, where DCt refers to the difference
between threshold cycles for NGF gene and b-actin gene.
Western Blot for NGF, Akt, and Phosphorylated
Akt in GECs
Proteins were isolated from GECs using standard RIPA
buffer. Western blot was performed to examine the
expression of NGF, phosphorylated Akt, Akt, and b actin
proteins using methods described in our previous studies.1,4
Antibodies used were as follows: NGF (1:250, sc 548; Santa
Cruz Biotechnology, Santa Cruz, CA), phosphorylated Akt
(1:500, 9271; Cell Signaling Technology), and Akt (1:1000,
9272; Cell Signaling Technology) or b actin (1:1000, A5316;
Sigma, St. Louis, MO).
NGF Immunostaining
The expression of NGF in aging GECs was examined by
immunofluorescence and immunoperoxidase staining using
NGF-specific antibody (sc 548; Santa Cruz Biotechnology). Rat
and human gastric mucosal specimens were immunostained
with NGF-specific antibody (1:100, sc 548; Santa Cruz
Biotechnology) using methods described previously in our
studies.1,27 We also performed dual-immunofluorescence
staining for NGF (red) and VEGF (green) in rat GU specimens
obtained 21 days after GU induction using standard methods.
Briefly, tissue sections were immunostained using specific an-
tibodies for NGF and VEGF (1:100, AF-293-NA; R&D Systems)
and visualized using Alexa Fluor 488 anti-goat and Alexa Fluor
568 anti-rabbit secondary antibodies (1:200; Invitrogen) using
similar methods as described in our previous study.28 Coded
mucosal specimens were examined by 2 investigators with
expertise in gastrointestinal pathology. ECs lining the mucosal
vessels were identified easily and evaluated by these 2 in-
vestigators (AA andAST). NGF immunostaining in 10 randomly
selected mucosal fields per each specimen was quantified
bymeasuring the staining signal intensity usingMetaMorph7.0.
Gene Therapy of Aging GECs With LV-NGF
Aging GECs were transduced with LV-NGF and LV-GFP
(control; to determine transfection efficiency), provided by
Dr M. Tuszynski (Director, Center for Neural Repair, Uni-
versity of California, San Diego, CA), using methods
described previously.29 GECs were plated in 12-well plates
and respective wells were transduced with serial dilutions
of LV-GFP and LV-NGF in medium containing polybrene
linker. The LV-GFP transfection efficiency in aging GECs was
determined by counting the number of transduced green
Figure 1. Aging GECs have reduced in vitro angiogenesis
and decreased NGF expression vs young GECs.
(A) Aging GECs have significantly reduced in vitro
angiogenesis–endothelial tube formation vs young GECs at 6
hours. (B) Real-time reverse-transcription (RT)-PCR showed
reduced NGF mRNA expression in aging GECs vs young
GECs, and Western blot showed reduced NGF expression in
aging GECs vs young GECs. Data are means ± SD (N ¼ 6).
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total number of cells in the same field under low bright-field
illumination. The percentage of cells showing GFP-derived
fluorescence was calculated as the percentage of the total
number of cells.
F-Actin and G-Actin Staining in GECs
GECs were treated with PBS or NGF (100 ng/mL) for 1
hour after pretreatment with Latrunculin B (0.5 mmol/L for
30 min), a specific inhibitor of actin polymerization. F-actin
and G-actin were visualized by double staining using Alexa
Green-conjugated phalloidin (2 U/100 mL; Invitrogen) to
detect F-actin and Alexa Red–conjugated DNase I (5 mg/100
mL; Invitrogen) to detect G-actin, as described similarly in
our previous studies.27,30
Cell Migration Assay
We performed cell migration assays by making stan-
dardized excisions in confluent GEC monolayers and
measured the number of cells that migrated into the
denuded area in response to NGF and Latrunculin B. Aging
GECs were seeded in 6-well plates and grown to confluence.
Cell monolayers were wounded by using a razor blade as
described in our previous studies.27,30 Cells were treated
with PBS or NGF (100 ng/mL) for 24 hours after pretreat-
ment with Latrunculin B (0.5 mmol/L) for 30 minutes. Cells
were stained with H&E and the migration rate was deter-
mined under an inverted microscope, as described similarly
in our previous studies.27,30
SRF Silencing
GECs were treated with either nonsilencing scrambled
control (control siRNA, 100 nmol/L; Qiagen) or SRF-specific
siRNA (SRF siRNA, 100 nmol/L; Qiagen) for 72 hours using
methods similar to those described in our previous study.4
Transfected GECs were used to study the effects of SRF
silencing on in vitro angiogenesis and cell proliferation. The
siRNA transfection efficiency in GECs was determined using
incorporation of Alexa Fluor 488–labeled siRNA and was 87%.
In Vivo Studies Aimed to Determine NGF
Expression in Aging Rat Stomach in Response to
Injury and to Determine Whether Local NGF
Therapy Increases Angiogenesis and Improves
GU Healing in Aging Rats
We used a well-established, in vivo model of GUs in rats to
determine the expression and role of NGF in GU healing. GUs
were induced in 24-month-old aging rats using local appli-
cation of acetic acid similar to our previous studies.13,31,32
We examined the expression of NGF in ECs lining the
gastric mucosal vessels in young and aging rats at baseline
and 3 weeks after injury (N ¼ 10 per group). Cell prolifera-
tion was examined by immunostaining for proliferating cell
nuclear antigen (PCNA) as in a previous study33 using spe-
cific anti-PCNA antibody (1:100, MAB424; Chemicon; Milli-
pore Sigma, Burlington, MA). The rate of PCNA-positive ECs
was expressed as the ratio of positively stained ECs to thetotal EC count and expressed relative to that for normal
gastric mucosa of young rats. We next performed in vivo
studies to determine whether NGF therapy increases angio-
genesis and improves gastric ulcer healing in aging rats. In
separate groups of rats, 30 minutes after GU induction and
once more at 3 days after GU induction, either PBS (control)
or NGF (100 mg/kg body weight in 200 mL PBS, N2513;
Sigma) was injected into the submucosa in 4 quadrants at the
site of GU induction (N ¼ 11 per group). Three weeks after
GU induction, rats were anesthetized and mucosal blood flow
in the scar and/or ulcer margin was determined by a laser
Doppler flow meter (Vasomedics, Inc, St. Paul, MN) with a
probe applied gently to the mucosa similarly as in our pre-
vious study.1 The GU size was measured under a dissecting
microscope similarly as in our previous studies.1,13 Gastric
specimens were obtained after euthanasia and processed for
histology. Quantitative histologic assessments including
vascular density (number of blood vessels per mm2 of gastric
mucosa or granulation tissue) and quality of mucosal regen-
eration were performed as described in our previous study.13
In a separate study, 30 minutes after GU induction in aging
rats (N ¼ 6), 200 mL PBS (control) or fluorescein isothiocy-
anate (FITC)-labeled NGF (100 mg/kg body weight in 200 mL
PBS) was injected into 4 quadrants of the submucosa at the
GU base. Three weeks after GU induction, rats were eutha-
nized and gastric specimens were obtained for histology. We
examined the incorporation of FITC-labeled NGF into gastric
Figure 2. NGF treatment reverses impairment of angio-
genesis in aging GECs through PI3 kinase/Akt and mTOR
pathways. (A) NGF treatment dose-dependently increases
in vitro angiogenesis in aging GECs. Aging GECs were
treated with either PBS (control) or exogenous NGF (10,
50, 100, or 1000 ng/mL) and in vitro angiogenesis on
Matrigel was examined. Data are means ± SD (N ¼ 6).
Treatment of aging GECs with NGF dose-dependently
increased angiogenesis with the maximal threshold stimu-
lating dose of 100 ng/mL at 6 hours (P < .001). There was
no significant difference in angiogenesis between cells
treated with NGF 100 ng/mL and 1000 ng/mL. †P > .05
(NS). (B) In vitro angiogenesis on Matrigel at 6 hours in
aging GECs treated with PBS or recombinant rat NGF (100
ng/mL) with or without pretreatment with specific PI3 ki-
nase inhibitor (LY294002; 50 mmol/L for 30 minutes), or
mTOR inhibitor (rapamycin; 10 nmol/L for 60 minutes).
Short-term (6 hours) treatment with exogenous NGF
significantly increased in vitro angiogenesis and in aging
GECs by 1.5-fold and pretreatment with LY294002, and
rapamycin abolished the NGF-induced increase in angio-
genesis. Data are means ± SD (N ¼ 6). (C) Representative
Western blots for phosphorylated Akt (pAkt) and Akt
expression in aging GECs treated with exogenous NGF
(0.1 mg/mL) for 4 and 24 hours. Treatment of aging GECs
with exogenous NGF significantly increased Akt
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our previous pilot study in young rats.34
Immunostaining of Human Gastric Biopsy
Specimens
The use of archival human gastric mucosal biopsy
specimens for immunostaining was approved by the Insti-
tutional Review Board at VA Long Beach Healthcare System.
The human gastric biopsy specimens did not have any
specific patient identifiers and the only inclusion criteria
used were as follows: age, normal appearance on histology
(absence of GU), and the lack of H pylori and inflammation.
We used 10 specimens each of young individuals (age,40 y)
and aging individuals (age, 70 y), and immunostained
them for NGF identically as rat sections (described earlier).
Coded mucosal specimens were examined by 2 investigators
(A.A. and A.S.T.) experienced in gastrointestinal histopathol-
ogy. NGF immunostaining in gastric ECs of gastric blood
microvessels was quantified by measuring NGF signal in-
tensity in 10 randomly selected microvessels in each spec-
imen using the MetaMorph 7 video analysis system.
Statistical Analysis
Data are presented as means ± SD. Statistical significance
was analyzed by either the Student t test to compare data
between 2 groups, 1-way analysis of variance with the Tukey
multiple comparison post hoc testing for evaluating differ-
ences between multiple groups, or the Pearson correlation
using Prism software (GraphPad Software, Inc, La Jolla, CA).
A P value < .05 was considered statistically significant.
Results
NGF Expression Is Reduced in GECs of Aging
Rats and Strongly Correlates With the Impairment
of Angiogenesis in These Cells
In GECs isolated from aging rats (age, 24 mo; aging
GECs), in vitro angiogenesis was reduced significantly by
4.1-fold (P < .001) (Figure 1A). The expression of NGF
messenger RNA (mRNA) and NGF protein was lower by 4.2-
fold and 3.0-fold, respectively, vs GECs isolated from young
rats (age, 3 mo; young GECs) (P < .001) (Figure 1B). These
results showed that angiogenesis is impaired in aging GECs
and that this impairment closely correlates with the reduced
NGF protein expression in these cells (correlation coeffi-
cient: r ¼ 0.996; P < .01).
NGF Treatment Reverses Impaired Angiogenesis
in Aging GECs Through PI3 Kinase/Akt and
mTOR Pathways
We next examined whether NGF treatment could reverse
impairment of angiogenesis in aging GECs and the possiblephosphorylation at 4 and 24 hours. Data are means ± SD
(N ¼ 3). The Student t test and 1-way analysis of variance
with the Tukey multiple comparison test were used to
determine statistical significance between 2 or multiple
groups, respectively.
Figure 3. NGF gene therapy increases NGF expression in aging GECs, reverses impaired in vitro angiogenesis, and
reduced cell proliferation. Aging GECs were transduced with human LV-NGF in medium containing polybrene linker. Mock
transductions in aging GECs performed using polybrene linker without LV-NGF served as negative controls (-, control) for
LV-NGF gene therapy. The efficiency of transfection in aging GECs was determined using LV-GFP. (A) The percentage of LV-
GFP–transfected aging GECs showing GFP-derived fluorescence was 82% ± 6%. (B) Western blot for NGF showed that after
NGF gene therapy (þ), aging GECs express both endogenous (rat) NGF and human NGF from gene therapy vs negative
controls (-, control), which express only endogenous (rat) NGF. (C) NGF gene therapy with LV-NGF resulted in a significant
3.7-fold increase in in vitro angiogenesis at 6 hours in aging GECs vs negative controls (-, control). Panels are representative
images of capillary-like tube formation. Original magnification, 200. Data are means ± SD (N ¼ 6). (D) Immunofluorescence
staining for NGF (red fluorescence) showed that NGF gene therapy in aging GECs strongly increased the expression of NGF by
3.3-fold and induced long filopodia (arrows) vs aging GECs without gene therapy (negative controls). (E) Immunoperoxidase
staining for NGF showed that NGF gene therapy of aging GECs induced a significant increase in NGF expression (brown
staining) and extensive long filopodia (arrows) reflecting a change in these cells to an angiogenic phenotype; aging GECs
without gene therapy (negative controls) have minimal NGF expression and lack filopodia. Data are means ± SD (N ¼ 6).
(F) Cell proliferation assessment after LV-NGF gene therapy of aging GECs. LV-NGF gene therapy of aging ECs significantly
increased cell proliferation. The Student t test and 1-way analysis of variance with the Tukey multiple comparison test were
used to determine statistical significance between 2 or multiple groups, respectively.
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Figure 4. Effect of NGF on actin polymerization and cell migration in aging GECs. Young and aging GECs were treated
with PBS or NGF (100 ng/mL) for 1 hour after pretreatment with Latrunculin B (0.5 mmol/L for 30 minutes), a specific inhibitor of
actin polymerization. (A) Representative photomicrographs of young and aging GECs showing visualization of F-actin and
G-actin by double staining using Alexa Green–conjugated phalloidin to detect F-actin and Alexa Red–conjugated DNase I to
detect G-actin. NGF treatment induced formation of extensive F-actin stress fibers and an increased F:G actin ratio in young
and aging GECs. Treatment with Latrunculin B inhibited NGF-induced F-actin polymerization. (B) NGF treatment significantly
increased the migration rate in young and aging GECs, but this effect was abolished by treatment with Latrunculin B. Data are
means ± SD (N ¼ 6). The Student t test and 1-way analysis of variance with the Tukey multiple comparison tests were used to
determine statistical significance between 2 or multiple groups, respectively.
2018 NGF and Angiogenesis in Aging Gastric Mucosa 205underlying mechanisms. NGF stimulated in vitro angiogen-
esis in aging GECs in a dose-dependent manner, and the
maximal threshold dose of NGF was 100 ng/mL (Figure 2A).
This NGF dose in aging GECs was similar to the maximal
threshold stimulating dose of 100 ng/mL NGF that
increased angiogenesis in young GECs.35 Treatment with
exogenous NGF (100 ng/mL) significantly increased in vitro
angiogenesis by 1.5-fold (P < .001) in aging GECs. This ac-
tion of NGF was completely abolished by pretreatment with
the specific PI3 kinase inhibitor LY294002, or mTOR in-
hibitor rapamycin (Figure 2B). Cell viability studies showed
that treatment with PI3 kinase and mTOR inhibitors (at the
doses used) did not affect viability of GECs. Because PI3
kinase catalyzes one of the steps upstream of Akt activation
(phosphorylation), we next examined the effect of NGFtreatment on Akt phosphorylation in aging GECs. Treatment
of aging GECs with exogenous NGF resulted in a significant
increase in Akt phosphorylation (Figure 2C).Impaired Angiogenesis in Aging GECs Is Owing
to Reduced NGF and Can Be Reversed by NGF
Gene Therapy
To determine a causal relationship between NGF defi-
ciency and impaired angiogenesis in aging ECs, we exam-
ined whether overexpression of NGF could reverse the
impairment of angiogenesis in aging GECs. We performed
NGF gene therapy using lentiviral human NGF (LV-NGF) to
increase NGF expression in aging GECs. The efficiency of
transfection in aging GECs was determined using lentiviral
Figure 5. SRF silencing abolishes NGF-induced angio-
genesis and proliferation of aging GECs. SRF was silenced
in aging GECs using specific siRNA, and the effect of SRF
silencing on in vitro angiogenesis on Matrigel and on GEC
proliferation was determined in the presence or absence of
NGF. (A) SRF silencing using specific siRNA significantly
reduced in vitro angiogenesis in aging GECs (vs cells treated
with scrambled [control siRNA]). This reduction in in vitro
angiogenesis by SRF siRNA was not affected by treatment
with exogenous recombinant rat NGF. Data are means ± SD
(N ¼ 6). (B) SRF silencing significantly reduced NGF-induced
proliferation aging GECs (vs cells treated with scrambled
[control siRNA]). Data are means ± SD (N ¼ 6).
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GFP–transfected cells showing GFP-derived fluorescence
(Figure 3A) was 82% ± 6%. NGF gene therapy significantly
increased NGF expression in aging GECs at 72 hours after
LV-NGF transduction to a level similar to that present in
control (nontreated) young ECs (Figure 3B), and almost
completely reversed the impaired angiogenesis in aging
GECs as evidenced by more than a 3-fold increase in
capillary-like endothelial tube formation (P < .001)
(Figure 3C). Thus, restoring NGF levels in aging GECs to
levels comparable with young GECs resulted in almost
complete restoration of angiogenesis.
NGF gene therapy of aging GECs induced extensive long
filopodia in these cells (Figure 3D and E), reflecting a switch
to an angiogenic phenotype. Interestingly, NGF was strongly
expressed in the filopodia, indicating its interactions with
cytoskeletal proteins during filopodia formation. NGF gene
therapy of aging GECs also significantly increased these
cells’ proliferation vs appropriate controls (P < .001)
(Figure 3F).
Because angiogenesis requires EC cell migration, pro-
liferation, reorganization of cytoskeletal structures, poly-
merization of G-actin into F-actin, and the assembly of F-
actin into stress fibers,27,30 we next examined the effect of
NGF treatment on F-actin and G-actin expression in young
and aging GECs by double staining using Alexa
Red–conjugated DNase I (Thermo Fisher Scientific) to
detect G-actin and Alexa Green–conjugated phalloidin
(Thermo Fisher Scientific) to detect F-actin. NGF treatment
induced the formation of extensive F-actin stress fibers
with a concurrent G-actin reduction (Figure 4A) in young
and aging GECs, these effects were abolished by pretreat-
ment with Latrunculin B. In addition, we performed cell
migration assays and determined the number of cells that
migrated across standardized excisions into the denuded
area in response to NGF and the effect of Latrunculin B.
NGF treatment increased cell migration in young and aging
GECs, and this effect was inhibited by pretreatment with
Latrunculin B (Figure 4B).
We next examined the effect of SRF on NGF-induced
angiogenesis. SRF was silenced in aging GECs using spe-
cific small interfering RNA (siRNA), and the effect of SRF
silencing on in vitro angiogenesis on Matrigel (Thermo
Fisher Scientific) and on GEC proliferation was determined
in the presence or absence of NGF. SRF silencing completely
abolished NGF-induced angiogenesis (Figure 5A) and pro-
liferation of aging GECs (Figure 5B).
NGF Expression is Reduced In Vivo in Gastric
ECs of Aging Rats and Local NGF Therapy of
Gastric Ulcers in Aging Rats Increases
Angiogenesis, Accelerates Gastric Ulcer Healing,
and Improves Mucosal Regeneration in Gastric
Ulcer Scars
Next, we examined the expression of NGF in GECs lining
gastric blood vessels in young and aging rats at baseline and
3 weeks after injury using a well-established, in vivo model
of gastric ulcers (GUs) in rats (Figure 6). These studiesshowed that NGF expression is reduced significantly in ECs
of mucosal and submucosal vessels in both normal and ul-
cerated gastric mucosa of aging rats compared with young
rats (Figure 6C and F).
GEC proliferation in gastric mucosa of young and aging
rats was examined by immunostaining for PCNA. In aging
rats, GEC proliferation was reduced significantly in both
normal and ulcerated gastric mucosa by 46% ± 5% and
31% ± 2%, respectively, vs young rats (Figure 7).
We also examined whether local treatment of GUs in
aging rats with NGF protein could improve in vivo angio-
genesis and accelerate GU healing. GUs were induced in
aging rats and either phosphate-buffered saline (PBS)
(control) or NGF (100 mg/kg body weight in 200 mL PBS)
was injected into the submucosa at the site of GU induction
twice (at 30 minutes and at 3 days) after GU induction, and
mucosal blood flow, microvessel density, GU, or scar size
and mucosal regeneration was examined 3 weeks after GU
induction. This local treatment of GUs in aging rats with NGF
significantly increased angiogenesis as reflected by
augmented mucosal blood flow in GU scars or GU margins
by 37% (vs PBS-treated control) (Figure 8A) and increased
vascular density in granulation tissue (Figure 8B).
Figure 6. NGF expression in normal and ulcerated mucosa of young and aging rats. Immunostaining for NGF in gastric
mucosa of young (A and D) and aging (B and E) rats. Quantitative analysis of NGF immunostaining showed reduced NGF
expression in ECs of mucosal (C) and submucosal (F) vessels in both normal and ulcerated gastric mucosa of aging rats
compared to young rats. Scale bars: 20 mm. *P< .05; **P< .005. Student’s t-test and one-way analysis of variance with Tukey’s
multiple comparison tests were used to determine statistical significance between 2 or multiple groups, respectively.
2018 NGF and Angiogenesis in Aging Gastric Mucosa 207NGF treatment also dramatically accelerated GU healing
as reflected by reduced size of GUs (Figure 8C) and
improved quality of mucosal regeneration (Figure 8D). In
the PBS-treated control group healing was impaired and
regenerating glands were dilated and distorted compared
with the NGF-treated group. We also examined the expres-
sion of NGF and VEGF in ulcerated gastric mucosa of rats
treated with PBS and NGF. In PBS-treated control aging rats,
VEGF was expressed in ECs lining the mucosal vessels, and
NGF and VEGF were weakly expressed in the GU granulation
tissue (Figure 9A). In aging rats treated with NGF, the
expression of NGF was increased significantly in GU gran-
ulation tissue and ECs by 1.6-fold (P < .001) vs PBS treat-
ment (Figure 9A).
In a separate group of aging rats, we injected FITC-
labeled NGF to the GU base 30 minutes after GU induc-
tion. Three weeks after GU induction, we examined the
incorporation of NGF into ulcerated gastric mucosa and
submucosa under an epifluorescence microscope asdescribed in our previous pilot study.34 Locally injected
FITC-labeled NGF was incorporated and retained in ECs of
blood vessels of GU granulation tissue and mucosal scar in
aging rats (Figure 9B).NGF Expression Is Reduced in Gastric Mucosal
ECs of Aging Individuals
We immunostained endoscopic human gastric biopsy
specimens of young individuals (age, 40 y) and aging in-
dividuals (age, 70 y) (n ¼ 10 specimens per group) using
specific NGF antibody. In the gastric mucosa of young in-
dividuals, NGF was expressed in ECs of mucosal blood
vessels and in some epithelial cells (Figure 10A). In gastric
specimens from aging individuals NGF signal intensity in
ECs was reduced dramatically (Figure 10B) compared with
gastric specimens from young individuals. Quantitative
evaluation of NGF immunostaining showed a significant 5.5-
fold reduction in NGF expression in ECs of mucosal vessels
Figure 7. GEC proliferation in normal and ulcerated
gastric mucosa of young and aging rats determined by
PCNA staining. In aging rats, the number of PCNA-positive
ECs was reduced by 46% ± 5% in normal gastric mucosa
and by 31% ± 2% in ECs in ulcerated gastric mucosa
compared with young rats. PCNA staining in normal gastric
mucosa of young rats is expressed as 100%.
208 Ahluwalia et al Cellular and Molecular Gastroenterology and Hepatology Vol. 6, No. 2in the gastric mucosa of aging vs young individuals
(P < .001) (Figure 10C).
Discussion
Angiogenesis is impaired in aging tissues including aging
gastric mucosa and results in inadequate revascularization
and delayed injury healing.3,14,15,36 However, the mecha-
nisms are not fully elucidated and the role of NGF inFigure 8. Local NGF therapy of GUs in aging rats increases
proves quality of mucosal regeneration. In aging rats, either
was locally injected to the ulcer base after GU induction. Muc
regeneration was examined 3 weeks after GU induction. Local N
mucosal blood flow in GU scars/margins by 37% vs control, a
base of the GU scar/margin by 62% vs control, both showin
healing as reflected by >5-fold reduction in GU size. (D) Mucos
GU scars of NGF-treated rats vs poor, disorganized, and abnorm
in the control group.aging-related angiogenesis impairment is not known. This
study showed that ECs isolated from gastric mucosa of aging
rats (aging GECs) have reduced expression of NGF and
impaired angiogenesis, and, importantly, that NGF therapy
restores in vitro angiogenesis in these aging ECs. Further-
more, this study also showed reduced NGF expression in
GECs in gastric mucosa of aging human beings and rats, and
that local NGF therapy significantly reversed both impaired
angiogenesis and delayed GU healing in aging rats.
The rationale for the study on the role of NGF in impaired
angiogenesis in aging stemmed from our previous study,
which showed that NGF is critical for angiogenesis in young
GECs. NGF silencing in young GECs using specific siRNA
inhibited angiogenesis in these cells.35 Interestingly, the in-
hibition of angiogenesis after NGF silencing in young GECs
could be reversed only by exogenous NGF but not by VEGF,
indicating that the angiogenic action of NGF in gastric
mucosal ECs is not dependent on VEGF.35 We also showed in
young GECs that NGF increases mitochondrial membrane
potential (MMP), up-regulates insulin-like growth factor 1,
and protects those cells from nonsteroidal anti-inflammatory
drug (NSAID)-induced injury by preventing MMP depolari-
zation MMP and reduction in in vitro angiogenesis.25
Our present in vitro studies in aging GECs showed that
NGF gene therapy increased NGF expression in these cells
and dramatically reversed impaired angiogenesis. Because
NGF gene therapy significantly increased NGF expression inangiogenesis, accelerates gastric ulcer healing, and im-
PBS (control) or NGF (100 mg/kg body weight in 200 mL PBS)
osal blood flow, microvessel density, GU size, and mucosal
GF treatment of GUs in aging rats (A) significantly increased
nd (B) increased vascular density in granulation tissue at the
g increased angiogenesis. (C) NGF therapy accelerated GU
al histology showed better regeneration of gastric mucosa in
al regeneration (eg, large, dilated, irregular abnormal glands)
Figure 9. Local NGF therapy of GUs in aging rats in-
creases NGF expression. (A) Dual immunostaining for NGF
(red) and VEGF (green) in gastric mucosa of aging rats after
local treatment with PBS (control) or NGF (100 mg/kg body
weight) 3 weeks after GU induction. In PBS-treated control
aging rats, VEGF was expressed modestly in ECs lining the
mucosal vessels, and NGF and VEGF were expressed weakly
in the GU granulation tissue. In aging rats treated with NGF,
expression of NGF was increased significantly in GU granu-
lation tissue and ECs by 1.6-fold (P < .001) vs PBS treatment.
Some of the ECs lining mucosal vessels (asterisk) expressed
both NGF and VEGF (yellow staining). Local NGF treatment of
GUs in aging rats increased NGF expression in ECs lining the
mucosal vessels. (B) Locally injected FITC-labeled NGF
incorporated into the GU base and was present (retained) at 3
weeks in ECs lining submucosal blood vessels (asterisk), and
mucosal microvessels (arrows) of GU scars in aging rats. Rats
injected with PBS showed low-level background auto-
fluorescence in the GU scar (negative control). Scale bars:
100 mm.
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treated young GECs, this clearly showed a causal relationship
between NGF deficiency and impaired angiogenesis in aging
ECs. This cause–effect relationship between NGF expression
in gastric ECs and angiogenesis is underscored further by
showing in our previous study that NGF silencing in young
GECs inhibited angiogenesis in these cells,35 comparable
with the level of aging GECs. Furthermore, this study showed
that NGF gene therapy induces extensive long filopodia inaging GECs, which reflect a switch to an angiogenic pheno-
type in these cells. Interestingly, NGF was strongly expressed
in the filopodia, indicating its binding to and interactions
with cytoskeletal elements during filopodia formation. One
of the key steps during angiogenesis is the formation of
filopodia, which send guidance cues that direct endothelial
tube formation and branching.37–41 VEGF is a major inducer
of filopodia in branching vessels during angiogenesis.42,43
Our novel findings indicate that NGF can induce an angio-
genic phenotype in aging GECs similar to that shown to be
induced by VEGF in young ECs in previous studies.42,43
Actin polymerization to F-actin and formation of stress
fibers are critical for EC migration and endothelial tube
formation, which are critical steps of angiogenesis. Here, we
showed that NGF induces G-actin polymerization to F-actin
and formation of actin stress fibers in aging GECs, and that
these cytoskeletal rearrangements are critical for NGF’s
angiogenic action. Latrunculin B, which inhibits G-actin
polymerization, abolished NGF-induced in vitro angiogen-
esis in aging GECs. This shows that NGF stimulates poly-
merization of G-actin into F-actin and the formation of stress
fibers in GECs that are critical for these cells’ migration and
angiogenesis.
PI3 kinase/Akt signaling is critical for EC survival,
cytoskeletal rearrangements (eg, lamellipodia and filopodia
formation, migration, and angiogenesis),44,45 and mTOR
signaling is essential for sprouting angiogenesis in endo-
thelial cells.46 Our present study showed that PI3 kinase/
Akt and mTOR inhibitors abolished the angiogenic action of
NGF in aging GECs. This clearly indicates that NGF mediates
its actions on aging GECs through the PI3 kinase/Akt47 and
mTOR48 signaling pathways.
This study also explored the potential role of SRF in NGF-
induced angiogenesis in aging GECs. SRF was discovered in
1986 by Treisman,49 who showed that serum induces c-fos
expression in fibroblasts through activation of a transcrip-
tion factor, SRF, which binds to the serum response element
in the c-fos promoter. Subsequently, SRF has been shown to
regulate expression of numerous genes including those
involved in cytoskeletal rearrangements in several types of
cells.30 Our previous study showed that SRF is a down-
stream mediator of VEGF signaling in ECs and is a critical
requirement for VEGF-induced angiogenesis.30 In that study,
the knockdown of SRF protein levels in human and rat
endothelial cells abolished VEGF-induced in vitro angio-
genesis, impaired endothelial cell migration and prolifera-
tion, and inhibited VEGF-induced actin polymerization and
immediate early gene expression.30 Our present study
showed that NGF-induced angiogenesis in aging GECs is
dependent on SRF, and SRF silencing completely abolishes
NGF-induced angiogenesis in these cells. A recent study
showed that SRF is a major mediator of NGF-induced
mitogen-activated protein kinase kinase/extracellular
regulated kinase (MEK/ERK) and megakaryocytic acute
leukemia (MAL) signaling, and NGF-dependent target
innervation by embryonic sensory neurons.50 Thus, the
present study uncovered a novel previously unrecognized
role of NGF and SRF in gastric ECs and regulation of
angiogenesis in aging rats (Figure 11).
Figure 10. NGF expression is reduced in gastric ECs of aging (age, ‡70 y) vs young (age, £40 y) individuals. (A and B)
Immunostaining for NGF in specimens of young individuals (age,  40 y) and aging individuals (age, 70 y) (N ¼ 10 specimens
per group). Immunostaining showed significantly reduced NGF expression in ECs lining gastric mucosal blood microvessels of
(B) aging individuals (arrows) compared with that of (A) young individuals. No staining was observed in tissue sections
incubated without primary antibody (negative control; lower right panels). (C) Quantitative evaluation of NGF immunostaining
signal showed significantly (5.5-fold) reduced NGF expression in ECs of mucosal vessels in gastric mucosa of aging vs young
individuals. Scale bars: 100 mm. The Student t test was used to determine statistical significance.
210 Ahluwalia et al Cellular and Molecular Gastroenterology and Hepatology Vol. 6, No. 2Our present in vivo studies showed that local NGF
treatment of GUs in aging rats increases angiogenesis,
dramatically accelerates GU healing, and improves the
overall quality of mucosal regeneration within the GU scar.
Furthermore, this study showed that locally injected FITC-
labeled NGF incorporated into ECs of blood vessels and
some epithelial cells of gastric tissues. Interestingly, NGF
treatment of GUs in aging rats resulted in a more complete
regeneration of gastric glandular structures in the ulcer scar
than local gene therapy of GUs in young rats with a local
injection of VEGF encoding naked DNA, as reported in our
previous study.13 Thus, this study uncovered a novel pre-
viously unrecognized role of NGF in gastric angiogenesis
and GU healing in aging rats and provided a rationale for a
clinical translation.
The paradigm of NGF reversing the aging-related
impairment of EC angiogenesis and cell proliferation (the
2 main characteristics of the aging EC phenotype) shown in
this study in regard to GECs may apply to other types of
cells and may have important implications for other aging
tissues. A previous study showed that lentiviral NGF injec-
ted into the basal forebrain of aged monkeys reversed
aging-related neuronal atrophy as reflected by a significant
recovery in number and size of cholinergic neurons to thelevels present in young monkeys.29 It is possible that the
beneficial effect of NGF gene therapy in that study was
owing in part to increased angiogenesis. Taken together,
these findings indicate a likely role of NGF deficiency in
aging of neural cells and non-neural cells (such as ECs), thus
providing a greater dimension to the concept of NGF defi-
ciency in aging tissues.
This study showed a strong expression of NGF in gastric
mucosal ECs of young individuals and significantly reduced
NGF expression in gastric mucosal ECs of aging individuals.
This clearly indicates human relevance of our experimental
findings and also can explain impaired angiogenesis and
delayed healing of injured gastric mucosa in aging
individuals.
Our article provides novel insight into mechanisms of
impaired gastric angiogenesis in aging. Aging gastropathy
and its consequences are clinically critical issues, espe-
cially because the aging US population is growing rapidly
and it is estimated that by the year 2030, approximately 70
million Americans will be older than 65 years of age. In-
dividuals older than 65 years of age have significantly
increased gastric injury from aspirin and other NSAIDs and
have an increased risk of tissue and organ injuries and
complications of GU.51–54 Prior upper gastrointestinal
Figure 11. Diagrammatic representation of mechanisms
and signaling pathways by which NGF promotes gastric
angiogenesis in aging GECs. The mechanisms and
signaling pathways mediating NGF’s actions on aging GECs
include activation of PI3 kinase and mTOR signaling, which
reverses impaired angiogenesis and cell proliferation, and
polymerization of G-actin to F-actin, which increases GEC
migration. These actions of NGF on aging GECs are depen-
dent on SRF protein expression. TrkA, tropomyosin receptor
kinase A (NGF receptor).
2018 NGF and Angiogenesis in Aging Gastric Mucosa 211clinical events (eg, ulcer), age 65 years, and low-dose
aspirin use are main risk factors for these complica-
tions.52 The risk of GU complications is 8-fold higher in
individuals 70 years of age vs subjects younger than age
50 years.54–57 Recent studies have indicated that the inci-
dence of non–H pylori, non-NSAID ulcers (termed idio-
pathic ulcers) is increasing and they constitute up to 30%
of all ulcers and patients with a history of idiopathic
bleeding ulcers have an increased risk of recurrent ulcer
bleeding and a high mortality rate.58–60 Therefore, the GU
recurrence and its complications remain an important
clinical issue, especially in aging and severely ill patients.
Our study provides a novel insight into novel mechanisms
and the regulatory role of NGF and angiogenesis in GU
healing and their relation to aging-related impairment of
these processes.
The stimulation of angiogenesis by NGF potentially may
involve activation of other growth factors (eg, VEGF).24,61–64
Previous studies, including our own, have examined the role
of other factors such as VEGF, epidermal growth factor,
basic fibroblast growth factor, phosphatase and tensin ho-
molog (PTEN), and survivin in aging, angiogenesis, and ulcer
healing.1,3,65–69 Some of these factors were reviewed in our
previous publications.5,6 The novel insight into mechanisms
of impaired gastric angiogenesis in aging provided in this
article can be potentially applicable to other areas of
mucosal healing in the gastrointestinal tract. Although we
fully recognize the potential role of other growth factors and
cytokines in angiogenesis, GU healing, and their impairmentin aging, we focused on NGF in this study. Further studies
are necessary to investigate the role of other growth factors
and cytokines in angiogenesis, GU healing, and their
impairment in aging.References
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